CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $278,000 | -69.8% | 3,826 | -53.6% | 0.03% | -66.7% |
| Q3 2021 | $922,000 | -28.8% | 8,239 | +3.0% | 0.09% | -30.8% |
| Q2 2021 | $1,295,000 | +37.3% | 8,002 | -1.8% | 0.13% | +19.3% |
| Q1 2021 | $943,000 | -8.3% | 8,145 | +32.7% | 0.11% | -12.8% |
| Q4 2020 | $1,028,000 | +68.8% | 6,138 | +4.2% | 0.12% | +13.6% |
| Q3 2020 | $609,000 | +46.4% | 5,890 | +11.1% | 0.11% | +23.6% |
| Q2 2020 | $416,000 | +49.6% | 5,300 | +2.9% | 0.09% | +34.8% |
| Q1 2020 | $278,000 | +62.6% | 5,150 | +51.5% | 0.07% | +73.7% |
| Q3 2019 | $171,000 | +31.5% | 3,400 | +28.3% | 0.04% | +26.7% |
| Q2 2019 | $130,000 | – | 2,650 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |